David E. Cohn

22.0k total citations · 2 hit papers
377 papers, 12.2k citations indexed

About

David E. Cohn is a scholar working on Reproductive Medicine, Obstetrics and Gynecology and Oncology. According to data from OpenAlex, David E. Cohn has authored 377 papers receiving a total of 12.2k indexed citations (citations by other indexed papers that have themselves been cited), including 157 papers in Reproductive Medicine, 149 papers in Obstetrics and Gynecology and 95 papers in Oncology. Recurrent topics in David E. Cohn's work include Endometrial and Cervical Cancer Treatments (143 papers), Ovarian cancer diagnosis and treatment (138 papers) and Uterine Myomas and Treatments (54 papers). David E. Cohn is often cited by papers focused on Endometrial and Cervical Cancer Treatments (143 papers), Ovarian cancer diagnosis and treatment (138 papers) and Uterine Myomas and Treatments (54 papers). David E. Cohn collaborates with scholars based in United States, Japan and Australia. David E. Cohn's co-authors include Jeffrey M. Fowler, Kimberly Resnick, David M. O’Malley, Floor Backes, Larry J. Copeland, David G. Mutch, Adrian A. Suarez, Debra L. Richardson, Leigh G. Seamon and Karuppaiyah Selvendiran and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Investigation and Journal of Clinical Oncology.

In The Last Decade

David E. Cohn

357 papers receiving 11.9k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The detection of differentially expressed microRNAs from the serum of ovarian cancer patients using a novel real-time PCR platform

2008 539 citations David E. Cohn et al. Gynecologic Oncology profile →
Phase III Trial of Four Cisplatin-Containing Doublet Combinations in Stage IVB, Recurrent, or Persistent Cervical Carcinoma: A Gynecologic Oncology Group Study

2009 497 citations Bradley J. Monk, D. Scott McMeekin et al. profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
David E. Cohn	5.0k	4.3k	2.9k	2.9k	2.3k	377	12.2k
Gabriella Ferrandina	4.6k 0.9×	5.7k 1.3×	4.6k 1.6×	4.8k 1.7×	2.0k 0.9×	496	15.8k
Thomas J. Herzog	6.1k 1.2×	6.2k 1.4×	1.8k 0.6×	3.2k 1.1×	1.4k 0.6×	334	13.3k
Pierluigi Benedetti Panici	6.7k 1.3×	6.6k 1.6×	2.8k 1.0×	3.6k 1.2×	1.3k 0.6×	566	16.0k
William A. Cliby	5.2k 1.0×	6.8k 1.6×	3.8k 1.3×	3.5k 1.2×	1.6k 0.7×	288	14.3k
Jalid Sehouli	3.8k 0.8×	7.8k 1.8×	5.8k 2.0×	5.9k 2.0×	3.2k 1.4×	866	19.2k
David G. Mutch	9.4k 1.9×	6.9k 1.6×	4.0k 1.3×	4.3k 1.5×	2.9k 1.3×	449	19.1k
Deborah K. Armstrong	2.9k 0.6×	8.1k 1.9×	3.0k 1.0×	4.3k 1.5×	1.4k 0.6×	206	14.0k
Barbara A. Goff	3.4k 0.7×	5.4k 1.3×	1.4k 0.5×	2.4k 0.8×	904 0.4×	231	10.2k
Jonathan S. Berek	7.4k 1.5×	8.1k 1.9×	1.9k 0.6×	4.3k 1.5×	1.2k 0.5×	297	16.6k
Mark F. Munsell	2.1k 0.4×	1.6k 0.4×	2.0k 0.7×	3.6k 1.2×	1.1k 0.5×	243	11.8k

Countries citing papers authored by David E. Cohn

Since Specialization

Citations

This map shows the geographic impact of David E. Cohn's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David E. Cohn with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David E. Cohn more than expected).

Fields of papers citing papers by David E. Cohn

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David E. Cohn. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David E. Cohn. The network helps show where David E. Cohn may publish in the future.

Co-authorship network of co-authors of David E. Cohn

This figure shows the co-authorship network connecting the top 25 collaborators of David E. Cohn. A scholar is included among the top collaborators of David E. Cohn based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David E. Cohn. David E. Cohn is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Dorayappan, Kalpana Deepa Priya, Dongju Park, Takahiko Sakaue, et al.. (2024). ISG15 mediates the function of extracellular vesicles in promoting ovarian cancer progression and metastasis. SHILAP Revista de lepidopterología. 3(2). e92–e92. 3 indexed citations

Backes, Floor, et al.. (2023). Epigenetic MMR defect identifies a risk group not accounted for through traditional risk stratification algorithms in endometrial cancer. Frontiers in Oncology. 13. 1147657–1147657. 10 indexed citations

Dorayappan, Kalpana Deepa Priya, Adrian A. Suarez, G. Larry Maxwell, et al.. (2023). Tissue factor as a novel diagnostic target for early detection of ovarian cancer using ultrasound microbubbles. Gynecologic Oncology. 173. 138–150.

Cohn, David E., et al.. (2021). Prehabilitation for medically frail patients undergoing surgery for epithelial ovarian cancer: a cost-effectiveness analysis. Journal of Gynecologic Oncology. 32(6). e92–e92. 24 indexed citations

Hong, Bangxing, Uksha Saini, David E. Cohn, et al.. (2020). Oncolytic HSV Therapy Modulates Vesicular Trafficking Inducing Cisplatin Sensitivity and Antitumor Immunity. Clinical Cancer Research. 27(2). 542–553. 23 indexed citations

Srivastava, Amit Kumar, Ananya Banerjee, Tiantian Cui, et al.. (2019). Inhibition of miR-328–3p Impairs Cancer Stem Cell Function and Prevents Metastasis in Ovarian Cancer. Cancer Research. 79(9). 2314–2326. 74 indexed citations

Dorayappan, Kalpana Deepa Priya, Miranda L. Gardner, Colin L. Hisey, et al.. (2019). A Microfluidic Chip Enables Isolation of Exosomes and Establishment of Their Protein Profiles and Associated Signaling Pathways in Ovarian Cancer. Cancer Research. 79(13). 3503–3513. 88 indexed citations

Saini, Uksha, Adrian A. Suarez, Shan K. Naidu, et al.. (2018). STAT3/PIAS3 Levels Serve as “Early Signature” Genes in the Development of High-Grade Serous Carcinoma from the Fallopian Tube. Cancer Research. 78(7). 1739–1750. 17 indexed citations

ElNaggar, Adam C., Erinn M. Hade, David M. O’Malley, et al.. (2018). Time to chemotherapy in ovarian cancer: Compliance with ovarian cancer quality indicators at a National Cancer Institute-designated Comprehensive Cancer Center. Gynecologic Oncology. 151(3). 501–505. 12 indexed citations

10.

Ko, Emily, Laura J. Havrilesky, Ronald D. Alvarez, et al.. (2018). Society of Gynecologic Oncology Future of Physician Payment Reform Task Force report: The Endometrial Cancer Alternative Payment Model (ECAP). Gynecologic Oncology. 149(2). 232–240. 9 indexed citations

11.

Piedmonte, Marion, Paul K. J. Han, Richard P. Moser, et al.. (2017). Factors Associated With Deciding Between Risk-Reducing Salpingo-oophorectomy and Ovarian Cancer Screening Among High-Risk Women Enrolled in GOG-0199: An NRG Oncology/Gynecologic Oncology Group Study. Obstetrical & Gynecological Survey. 72(6). 336–337. 1 indexed citations

12.

Cohn, David E., Laura Huffman, Ritu Salani, et al.. (2016). A Prospective, Comparative Study for the Evaluation of Postoperative Pain and Quality of Recovery in Patients Undergoing Robotic Versus Open Hysterectomy for Staging of Endometrial Cancer. Journal of Minimally Invasive Gynecology. 23(3). 429–434. 18 indexed citations

13.

Esselen, Katharine M., Angel M. Cronin, Kristin Bixel, et al.. (2016). Use of CA-125 Tests and Computed Tomographic Scans for Surveillance in Ovarian Cancer. Obstetrical & Gynecological Survey. 71(11). 660–661. 13 indexed citations

14.

Wright, Alexi A., Angel M. Cronin, Dana Milne, et al.. (2015). Use and Effectiveness of Intraperitoneal Chemotherapy for Treatment of Ovarian Cancer. Obstetrical & Gynecological Survey. 70(11). 696–697. 5 indexed citations

15.

Felix, Ashley S., Louise A. Brinton, D. Scott McMeekin, et al.. (2015). Relationships of Tubal Ligation to Endometrial Carcinoma Stage and Mortality in the NRG Oncology/Gynecologic Oncology Group 210 Trial. Obstetrical & Gynecological Survey. 70(10). 624–626. 2 indexed citations

16.

Rath, Kellie S., Shan K. Naidu, Hemant K. Bid, et al.. (2014). HO-3867, a Safe STAT3 Inhibitor, Is Selectively Cytotoxic to Ovarian Cancer. Cancer Research. 74(8). 2316–2327. 76 indexed citations

17.

Mannel, Robert S., Mark F. Brady, Elise C. Kohn, et al.. (2010). GOG 175: A Randomized phase III trial of IV carboplatin (AUC 6) and paclitaxel 175 mg/m(2) Q 21 days x 3 courses plus low-dose paclitaxel 40 mg/m(2)/wk versus IV carboplatin (AUC 6) and paclitaxel 175 mg/m(2) Q 21 days x 3 courses plus observation in patients with early-stage ovarian carcinoma. Gynecologic Oncology. 116(3).

18.

Gius, David, Eric Y. Chuang, Sheng Feng, et al.. (2007). Profiling Microdissected Epithelium and Stroma to Model Genomic Signatures for Cervical Carcinogenesis Accommodating for Covariates. Cancer Research. 67(15). 7113–7123. 76 indexed citations

19.

Cohn, David E.. (2006). La naranja mecánica. 80–82. 3 indexed citations

20.

Jass, Jeremy R., Hiroshi Iino, Andrew Ruszkiewicz, et al.. (2000). Neoplastic progression occurs through mutator pathways in hyperplastic polyposis of the colorectum. Gut. 47(1). 43–49. 194 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact